Rx License-Rx

18-8664-TpNCS

Intranasal Dantrolene Nanoparticle Use For Treatment Of Alzheimer's Disease

Intranasal delivering of dantrolene nanoparticles could potentially be used to inhibit memory loss and reduce amyloid plaques in patients with Alzheimer's disease. Problem: Alzheimer’s disease (AD) is a devastating neurodegenerative disease. The deficit in the development of new drugs targeting the amyloid pathology over the past several decades warrants exploration of alternative pathways that could be the primary cause of AD cognitive dysfunction. Solution: Disruption of intracellular calcium homeostasis by over activation of ryanodine receptor (RYRs) and/or NMDA receptors contributes to synaptic dysfunction even before the appearance of amyloid and tau pathology and symptoms of cognitive dysfunction in AD. Dr. Wei at the University of Pennsylvania has evaluated dantrolene, a ryanodine receptor antagonist, as a potential treatment for treatment of AD. Intranasal administrating of dantrolene nanoparticles showed improved brain uptake...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Inflammation

Indication: COVID-19

Modality: Small Molecule

Focus tags: Inflammation, Neurology, Cardiometabolic, Infectious Disease

Technology tags: Small Molecule, Drug Delivery, Biomanufacturing, Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: US Patent Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Inflammation. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is COVID-19. Public description: Intranasal delivering of dantrolene nanoparticles could potentially be used to inhibit memory loss and reduce amyloid plaques in patients with Alzheimer's disease. Problem: Alzheimer’s disease (AD) is a devastating neurodegenerative.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Eli Lilly — Neurodegeneration leadership and biomarker-driven trial infrastructure. Biogen — CNS portfolio gap-filling and translational neurology focus. Roche — CNS diagnostics, biomarkers, and global development scale.

Development Strategy to Increase PoS

First indication: COVID-19

Study design: Mechanism-first biomarker study before any broad symptomatic endpoint trial.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.